Established supply capacity to enable broad, equitable ......Established supply capacity to enable...
1
Established supply capacity to enable broad, equitable access towards 3bn doses worldwide R-Pharm Doses TBC SK Bioscience 20m EU Commission Up to 400m UK 100m Fiocruz 100m Carlos Slim (Liomont/Mabxience) 150m CSL 53.8m Japan 120m Canada 20m US 300m Israel 10m SBS, SCG Doses TBC SII 1 bn 1 Establishing parallel supply agreements to ensure global access: Brazil (Fiocruz) LatAm (Ex Brazil) Japan China South Korea Russia with export to MEA, CIS, Balkans (R-Pharm) July USA May UK April Europe August Australia September SII (LMIC) June Canada November Israel CEPI-GAVI COVAX SE Asia October Continued engagement with intl. orgs and govts to drive equitable access CEPI-Gavi / COVAX – 170m = Countries that have committed to the COVAX Facility as of December 15 BioKangtai Up to 200m New Zealand 7.5m New Zealand December
Transcript of Established supply capacity to enable broad, equitable ......Established supply capacity to enable...
Established supply capacity to enable broad, equitable access towards 3bn doses worldwide
R-Pharm
Doses TBC
SK Bioscience
20mEU Commission
Up to 400m
UK
100m
Fiocruz
100m
Carlos Slim
(Liomont/Mabxience)
150m
CSL
53.8m
Japan
120m
Canada
20m
US
300m
Israel
10m
SBS, SCG
Doses TBC
SII
1 bn
1
Establishing parallel supply
agreements to ensure global
access:
Brazil (Fiocruz)
LatAm (Ex Brazil)
Japan
China
South Korea
Russia with export
to MEA, CIS, Balkans
(R-Pharm)
July
USAMay
UKApril
EuropeAugust
AustraliaSeptember
SII (LMIC)June
CanadaNovember
Israel
CEPI-GAVI COVAX
SE AsiaOctober
Continued engagement with intl. orgs and govts to drive equitable access
CEPI-Gavi / COVAX – 170m
= Countries that have committed to the COVAX Facility as
of December 15
BioKangtai
Up to 200m
New Zealand
7.5m
New ZealandDecember
